Literature DB >> 21429681

[Managing the risk of wound tetanus in family practice].

C Barjat1, R Charles, F Lucht, P Frappé.   

Abstract

OBJECTIVES: The study objectives were to assess how GPs manage the risk of tetanus in wounds, compared to the French Health Ministry guidelines on tetanus toxoid vaccination and immunoglobulin injections.
DESIGN: A cross-sectional survey was made using an online questionnaire sent to 3,165 GPs in the French Rhône-Alpes region.
RESULTS: The answer rate was 9.1%. Overall, 64.4% of GP complied to recommendations. The best observance was noted for minor risk wounds and for patients whose last booster vaccination was less than 5years old (P<0.05). Generally, GPs underused tetanus toxoid vaccination (-17.1%) and overused immunoglobulin injections (+37.1%). The main difficulties encountered were assessing the patient and his wound, misuse of immunoglobulin injections, and ignorance of recommendations.
CONCLUSIONS: The higher the tetanic risk, the less recommendations were observed. A quick diagnostic test and a better availability of new easier to memorize recommendations should help GPs optimize their practices.
Copyright © 2011. Published by Elsevier SAS.

Entities:  

Mesh:

Year:  2011        PMID: 21429681     DOI: 10.1016/j.medmal.2010.12.014

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  2 in total

1.  A survey of French general practitioners on the epidemiology of wounds in family practice.

Authors:  Marianne Sarazin; Florence Roberton; Rodolphe Charles; Alessandra Falchi; Solange Gonzales Chiappe; Thierry Blanchon; Frédéric Lucht; Thomas Hanslik
Journal:  Int J Gen Med       Date:  2015-06-16

2.  The use of tetanus post-exposure prophylaxis guidelines by general practitioners and emergency departments in the Netherlands: a cross-sectional questionnaire study.

Authors:  Robine Donken; Nicoline van der Maas; Corien Swaan; Tjerk Wiersma; Margreet Te Wierik; Susan Hahné; Hester de Melker
Journal:  BMC Fam Pract       Date:  2014-06-09       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.